Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 153 Jul 18 – Oct 15, 2026
- Disclosed funding
- $5.2B 123 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| CT Celaid TherapeuticsCompany profile Celaid Therapeutics develops cell therapies using technology that expands blood-forming stem cells outside the body. Celaid Therapeutics develops cell therapies using technology that expands blood-forming stem cells outside the body. | ¥400M | Series B second closeSeries B | Biotech | Japan | Investors | |
| O OmnioCompany profile Omnio develops a plasminogen-based biologic for chronic wounds, initially diabetic foot ulcers. Omnio develops a plasminogen-based biologic for chronic wounds, initially diabetic foot ulcers. | €2.9M | Funding roundUndisclosed | Biotech | Sweden | Investors Undisclosed | |
| M M-BasedCompany profile Ankara biomaterials company developing mushroom-based alternatives for industrial products. Ankara biomaterials company developing mushroom-based alternatives for industrial products. | ~$700K | Seed | Biotech, Climate tech | Türkiye | Investors | |
| AB Aptatek Biosciences, Inc.Company profile Aptatek Biosciences develops connected diagnostic tools for metabolic monitoring at home. Its investigational PheCheck programme measures blood phenylalanine for people with PKU. Aptatek Biosciences develops connected diagnostic tools for metabolic monitoring at home. Its investigational PheCheck programme measures blood phenylalanine for people with PKU. | Undisclosed | Initial close of financingUndisclosed | Biotech | United States | Investors | |
 AventixCompany profile Aventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results. Aventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results. | €1.2M | Pre-seed | Biotech | Sweden | Investors | |
| AP Astrocyte Pharmaceuticals Inc.Company profile Astrocyte Pharmaceuticals develops treatments intended to protect brain tissue after concussion, traumatic brain injury and stroke by targeting astrocytes. Astrocyte Pharmaceuticals develops treatments intended to protect brain tissue after concussion, traumatic brain injury and stroke by targeting astrocytes. | $9.5M | Series B | Biotech | United States | Investors | |
| V VytalyouCompany profile Vytalyou provides doctor-led preventive-health services combining diagnostics, personalised interventions and medically supervised care. Vytalyou provides doctor-led preventive-health services combining diagnostics, personalised interventions and medically supervised care. | ₹90M | Pre-Series ASeed | Biotech, Healthtech | India | Investors | |
 AnaCardioCompany profile AnaCardio develops oral medicines intended to improve heart muscle contraction in people with heart failure. AnaCardio develops oral medicines intended to improve heart muscle contraction in people with heart failure. | €62.5M | Series B | Biotech | Sweden | Investors | |
| AT Aptadir TherapeuticsCompany profile RNA therapeutics designed to restore expression of silenced genes RNA therapeutics designed to restore expression of silenced genes | €40M | Seed | Biotech | Italy | Investors | |
| a ai3BioCompany profile ai3Bio develops therapies designed to remove disease-causing Th17 immune cells, using antibody and lipid-nanoparticle platforms to address autoimmune disease. ai3Bio develops therapies designed to remove disease-causing Th17 immune cells, using antibody and lipid-nanoparticle platforms to address autoimmune disease. | $48M | Series A | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 18, 2026
- 1Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
10rounds0led - 2RA Capital Management
Circle Pharma, Inc., Solstice Oncology, Superluminal Medicines
8rounds2led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
6rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
6rounds2led - 5Oxford Science Enterprises
OMass Therapeutics, ReEmerge, Inc., Vivid Dx
5rounds0led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.